Uncategorized
Extended release ENV515 lowers IOP at 9 months with one dose
A “clinically meaningful” IOP reduction was maintained at 9 months with one dose of extended-release ENV515, according to an interim analysis of a phase 2 study released by Envisia Therapeutics.ENV515 (travoprost XR) is being evaluated in five patients during the ongoing multicenter 12-month safety and efficacy evaluation.